Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4082948 | 0.92 | SMYD2 (0.33) | SMYD2 | |
| SCHEMBL4093434 | 0.90 | SMYD2 (0.34) | HSD11B1SMYD2 | |
| SCHEMBL4328114 | 0.84 | HSD11B1 (0.33) | HSD11B1SMYD2 | |
| SCHEMBL4328118 | 0.84 | HSD11B1 (0.33) | HSD11B1SMYD2 | |
| SCHEMBL4336078 | 0.76 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL3621048 | 0.76 | SMYD2 (0.31) | SMYD2 | |
| SCHEMBL3621050 | 0.76 | SMYD2 (0.31) | SMYD2 | |
| SCHEMBL4089186 | 0.76 | SMYD2 (0.31) | SMYD2 | |
| SCHEMBL4092737 | 0.75 | SMYD2 (0.37) | HSD11B1SMYD2 | |
| SCHEMBL4082762 | 0.74 | SMYD2 (0.32) | HSD11B1SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | HSD11B1 985/4885SMYD2 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.